Abeona Therapeutics raises funds to launch cell therapy
EB-101 is being developed for recessive dystrophic epidermolysis bullosa. Credit: CDC on Unsplash. Clinical-stage biopharmaceutical firm Abeona Therapeutics has raised $25m from its current select investors to